MiNK Therapeutics Inc. has presented new translational data on its allo-iNKT cell therapy as a potential disease-modifying approach for idiopathic pulmonary fibrosis (IPF) at the Emerging Cell Therapies Meeting of the Keystone Symposia, held February 1-4, 2026, in Banff, Alberta, Canada. The data, presented by Dr. Terese Hammond, indicate a significant depletion of invariant natural killer T (iNKT) cells in lung-associated lymph nodes from patients with advanced IPF. The company reported that these findings support the rationale for iNKT cell replenishment strategies as a potential method to restore immune balance and support tissue repair in fibrotic lung disease. The results were presented at the Keystone Symposia on February 3, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646399-en) on February 04, 2026, and is solely responsible for the information contained therein.